JAXBIO TECHNOLOGIES LTD

Early diagnosis is the most important prognostic factor in most forms of cancer: a tumor identified at an early stage can have five-year survival rates ten times higher than one diagnosed at an advanced stage. Yet existing cancer screening programs cover only a handful of cancer types, are often invasive or expensive, and remain inaccessible to a large portion of the global population. JaxBio Technologies has identified this diagnostic gap as its core opportunity for impact. The company is developing a blood test for cancer diagnosis that is fast, affordable, and highly sensitive — a multi-cancer test capable of detecting tumor signals from a simple blood draw, without invasive procedures. The approach sits within the liquid biopsy category, one of the most active frontiers in modern oncological diagnostics, where the challenge is reducing false negatives and false positives to levels compatible with large-scale clinical use. The business model is B2B2C, with a software platform at the center of the offering. JaxBio targets clinical laboratories, oncologists, and diagnostic partners seeking to integrate multi-cancer blood tests into their service portfolio, while the ultimate impact falls on patients and healthcare systems that benefit from earlier and less costly diagnoses. The path to market runs through clinical validation and institutional partnerships — a process that demands methodological rigor and significant capital. The oncological diagnostics market is among the most attractive in healthtech, with growing demand from healthcare systems seeking ways to reduce the cost of cancer treatment by detecting disease earlier. JaxBio aims to become a significant player in this space with technology that could make cancer screening accessible to millions of people who currently have no access to preventive programs.